Progyny (NASDAQ: PGNY) reported Q4 EPS of $0.32, $0.22 better than the analyst estimate of $0.10. Revenue for the quarter came in at $269.94 million versus the consensus estimate of $273.61 million.

GUIDANCE:

Progyny sees FY2024 EPS of $1.54-$1.59, versus the consensus of $0.72. Progyny sees FY2024 revenue of $1.285-1.315 million, versus the consensus of $1.317 million.

First Quarter of 2024 Outlook:

Revenue is projected to be $285.0 million to $292.0 million, versus the consensus of $314.3, reflecting growth of 10% to 13%
Net income is projected to be $12.4 million to $13.7 million, or $0.12 to $0.13 per diluted share, on the basis of approximately 102 million assumed weighted-average fully diluted-shares outstanding
Adjusted EBITDA is projected to be $49.0 million to $51.0 million
Adjusted earnings per diluted share1 is projected to be $0.33 to $0.35, versus the consensus of $0.18.

For earnings history and earnings-related data on Progyny (PGNY) click here.